Viridian Therapeutics’ Lumvoa is approved for treating both the chronic and active phases of thyroid eye disease. This drug will offer patients an alternative to Tepezza, an Amgen drug that had been the only approved therapy for this inflammatory eye disorder.
The post FDA Approves Viridian’s Thyroid Eye Disease Drug, Competitor to a Blockbuster Amgen Med appeared first on MedCity News.
